JPRN-jRCT2080221744未知1 期
A phaseI,multiple-dose study of SA237
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients with rheumatoid arthritis of ≥ 6 months duration, diagnosed according to the revised 1987 ACR criteria
- •- Patients with CRP > ULN at screening
排除标准
- •- Any major episode of infection within 4 weeks prior to first dose
- •- Active chronic hepatitis B and C
- •- Active tuberculosis
- •- Active interstitial pneumonia
- •- History of serious allergic reactions
研究者
相似试验
进行中（未招募）
1 期
A Study Evaluating Venetoclax with Azacitidine in Subjects with PreviouslyUntreated Higher-Risk Myelodysplastic Syndromes (MDS)Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)MedDRA version: 20.0Level: LLTClassification code 10028532Term: MyelodysplasiaSystem Organ Class: 100000004864EUCTR2016-001657-41-ITABBVIE DEUTSCHLAND GMBH & CO. KG80
已完成
1 期
Phase I Study of TAS-115 in Patients with Advanced Solid TumorsJPRN-jRCT2080222284Taiho Pharmaceutical Co., Ltd.90
未知
1 期
Phase I Study of TAS-115 in Patients with Advanced Solid TumorsPatients with advanced solid tumorJPRN-jRCT2080221605Taiho Pharmaceutical Co., Ltd.85
已完成
1 期
K757 and K833 multiple-dose study in healthy subjectsHealthy subjectsISRCTN13328584Kallyope (United States)36
已完成
1 期
Study to investigate the safety of ENX-101 and how well it works in healthy volunteers.Epilepsy, spasticity and anxiety disordersISRCTN18262237Engrail Therapeutics, Inc.53